Hepatic Resection of Noncolorectal Nonneuroendocrine Metastases
|
|
- Brook Lang
- 5 years ago
- Views:
Transcription
1 Hepatic Resection of Noncolorectal Nonneuroendocrine Metastases Alan W. Hemming, * Tim D. Sielaff, Steven Gallinger, * Mark S. Cattral, * Bryce R. Taylor, * Paul D. Greig, * and Bernard Langer * Because hepatic resection is generally a safe procedure, the indications for resection of noncolorectal nonneuroendocrine (NCNNE) hepatic metastases have broadened. The prognostic features of NCNNE metastases treated surgically were reviewed to define better the value of resection. A retrospective review of patients undergoing liver resection for NCNNE metastases between 1978 and 1998 was undertaken. Thirty-seven patients were identified. Mean age was 56 years, with a median follow-up of 22 months. Primary tumor sites were grouped into gastrointestinal (GI) adenocarcinoma (small bowel, n 4; pancreas, n 2; esophagus, n 1) and other (renal cell, n 7; sarcoma, n 7; melanoma, n 5; adrenal, n 3; unknown adenocarcinoma, n 3; thyroid, n 2; testicular, n 1; ovarian, n 1; breast, n 1). All patients underwent surgery for cure. Metastases were synchronous in 14 patients. There was no surgical mortality. Overall 5-year survival rate was 45%. Five-year survival rates were better for patients with non GI-origin metastases (60% v 0%; P.01). Long-term survival was seen only in patients with non GI-origin metastases. The extent of resection, presence of synchronous metastases, or disease-free interval from time of original disease to presentation with liver metastases were not predictive of outcome. We conclude that patients with NCNNE hepatic metastases can undergo liver resection with an expectation of prolonged survival. However, patients with liver metastases from GI primary tumors other than the colorectum are unlikely to show extended survival. Copyright 2000 by the American Association for the Study of Liver Diseases L iver resection for metastatic colorectal cancer in selected patients has become the standard of care, with 5-year survival rates in the range of 25% to 40%. Improvements in surgical technique, patient selection, and perioperative care have increased the safety of liver resection such that even with extensive liver resections, surgical mortality in recent series is in the range of 0% to 5%. 1-3 Patients with neuroendocrine tumors metastatic to the liver have also been shown to benefit from resection, with improvements in both symptoms and survival. 4,5 The role of liver resection for noncolorectal nonneuroendocrine (NCNNE) tumors metastatic to the liver remains controversial. This report examines a single center s experience of resection of NCNNE tumors metastatic to the liver to assess whether results justify an aggressive surgical approach to this problem. Methods Thirty seven patients undergoing attempted curative hepatic resection for NCNNE metastases between 1978 and 1998 by the University of Toronto Hepatobiliary Surgery group were reviewed. Information was gathered from patient records, with patient follow-up by clinic visit or personal communication. Follow-up was complete in all patients. Curative resection was defined as a resection of all gross disease with negative pathological margins. Patients undergoing hepatic resection for direct tumor extension from the primary cancer were excluded. Records were reviewed for the following potential prognostic factors: (1) demographics, (2) primary tumor type, (3) synchronous versus metachronous presentation, (4) disease-free interval, (5) extent of hepatic resection, (6) curative versus noncurative resection, and (7) lobar versus bilobar involvement. Values are expressed as median and range. Parametric statistical analysis was performed using Student s t-test. Nonparametric statistical analysis was performed using chi-squared or Fischer s exact tests when appropriate. Survival was calculated using the Kaplan-Meier method, with comparison of groups using the log-rank test. Those variables found to be significant by univariate analysis were assessed by multivariate analysis using a Cox proportional hazard model, with significance specified as alpha equal to Results Thirty-seven patients underwent hepatic resection for NCNNE tumors during the period examined. Patient demographics are listed in Table 1. As the experience with liver resection accumulated, the number of liver resections for NCNNE tumors increased as well (1978 to 1984, n 6; 1985 to 1992, n 9; 1993 to 1998, n 22). Median age was 56 years (range, 25 to 80 years), with a man-woman ratio of 1.3:1. Thirty-eight percent of the patients presented with synchronous From the *Department of Surgery, University of Toronto, Toronto, Canada; and the Department of Surgery, University of Minnesota, Minneapolis, MN. Address reprint requests to Alan W. Hemming, MD, University of Florida College of Medicine, Department of Surgery, PO Box , Gainesville, FL Copyright 2000 by the American Association for the Study of Liver Diseases /00/ $3.00/0 Liver Transplantation, Vol 6, No 1 ( January), 2000: pp
2 98 Hemming et al Table 1. Characteristics of 37 Patients Undergoing Resection for NCNNE Metastases Total no. of patients 37 Men:women 21:16 Age (y) 56 (25-80) Presentation Synchronous 14 Metachronous 23 Symptoms Asymptomatic 19 Abdominal pain 7 Right upper quadrant fullness 2 Weight loss 2 Jaundice 2 Other 5 Site of disease Bilobar 9 Right lobe 21 Left lobe 7 Resection type Segmental 14 Lobectomy 17 Extended lobectomy 6 Table 2. Origin of Primary Tumor GI Origin Non-GI Origin Pancreas 2 Renal 7 Duodenum 2 Adrenal 3 Gastric 1 Testicular 1 Esophagus 1 Ovarian 1 Small bowel 1 Sarcoma 7 Melanoma 5 Unknown adenocarcinoma 3 Thyroid 2 Breast 1 lesions, whereas 62% had metachronous lesions. The median disease-free interval in all patients after primary treatment was 12 months (range, 0 to 21 years). The median disease-free interval in patients presenting with metachronous disease was 28 months (range, 2 months to 21 years). Fifty-one percent of the patients were asymptomatic at presentation. Metastatic lesions were in the right lobe in 57%, left lobe in 19%, and bilobar in 24%. The site of primary tumor is listed in Table 2. For purposes of analysis, tumors were classified into gastrointestinal (GI)-origin tumors or non GI-origin tumors. Adenocarcinomas of unknown origin were evaluated histologically using immunohistochemistry to attempt to rule out peripheral cholangiocarcinomas. GI tumors originated from the pancreas (n 2), duodenum (n 2), gastric area (n 1), esophagus (n 1), and small bowel (n 1). The two hepatic resections for pancreatic cancer were performed in patients with previous resections of papillary cystic carcinomas; 1 patient is alive and free of disease at 9 months, whereas the other died of recurrent disease at 26 months. Non GI-origin tumors included renal (n 7), sarcoma (n 7), melanoma (n 5), adrenal (n 3), unknown adenocarcinoma (n 3), thyroid (n 2), testicular (n 1), ovarian (n 1), and breast (n 1). Of the 7 patients with sarcoma, subtypes were leiomyosarcoma (n 2), uterine (n 2), cardiac (n 1), retroperitoneal (n 1), and abdominal wall (n 1). The 3 patients with unknown primary adenocarcinomas had undergone a histological review to attempt to rule out peripheral cholangiocarcinoma and had undergone upper and lower GI endoscopy, chest and abdominal computed tomographic scans, and mammography in the single woman. Two of 3 patients with unknown primary tumors were dead with widely metastatic disease within 10 months of resection; the third patient is alive and free of disease at 2 years. The 2 patients with testicular and ovarian tumors had undergone previous chemotherapy with failure to control hepatic disease. Surgical Results Of the 37 patients, 14 patients underwent segmental resection of one or more segments of Couinaud, 17 patients underwent formal right or left hepatic lobectomy, and 6 patients underwent right or left trisegmentectomy. Median surgical time was 4 hours (range, 1.5 to 6 hours). Median surgical blood requirement defined as transfusion during or within the first 24 hours of the procedure was0uofredcells (range, 0 to 12 U). Five patients had coexistent extrahepatic disease and underwent a simultaneous resection of another organ at the time of hepatic resection. Extrahepatic disease represented primary disease in 4 patients and metastatic disease in 1 patient. Four patients had positive microscopic margins and were therefore classified under noncurative procedures. Outcome There were no surgical deaths in this series. Median follow-up was 22 months, with no patients lost to follow-up. Actuarial survival at 1, 3, and 5 years was 85%, 55%, and 45%, respectively, with a median
3 Noncolorectal Nonneuroendocrine Metastases 99 Figure 1. Five-year overall actuarial survival in NCNNE patients undergoing hepatic resection for metastatic disease was 45%. survival of 46 months (95% confidence interval, 14 to 79 months; Fig. 1). There are 5 survivors at 5 years, to date. These include 2 patients with primary adrenocortical tumors, 2 patients with sarcoma, and 1 patient with metastatic renal cell carcinoma. By univariate analysis, only tumor origin (Fig. 2) and curative resection (Fig. 3) were predictive of outcome. These two factors remained significant on multivariate analysis (Table 3). Disease-free interval of 36 months or greater was not predictive of outcome (Fig. 4). Discussion Surgical resection is the only potentially curative treatment for most cancers metastatic to the liver. The Figure 3. Patients with positive microscopic margins did significantly worse than patients who received curative procedures (P.03). benefit of hepatic resection in the setting of hepatic metastases from colorectal primary tumors has been well documented, with a surgical mortality rate less than 5% and 5-year survival rates reported between 25% and 40%. 1-3 Hepatic resection for neuroendocrine metastases has also been shown to be of benefit for both symptomatic relief and prolonged survival. 4,5 It has been less well documented that resection of NCNNE hepatic metastases is of benefit. In our study, the overall 5-year survival rate was 45% for resection of NCNNE hepatic metastases, which compares favorably with results reported for colorectal metastases. Recent studies by Harrison et al 6 and Berney et al 7 have shown 5-year survival rates of 37% and 27%, respectively, in reports of hepatic resection for noncolorectal primary tumors. It is Table 3. Univariate and Multivariate Analysis Shows Only Tumor Origin and Curative Resection Are Significant Predictors of Outcome Figure 2. Patients who underwent resection with noncolorectal GI-origin tumors had a significantly worse prognosis than patients with non GI-origin tumors (P.02). Univariate P Multivariate P Type of liver resection NS Unilateral v bilateral NS Extrahepatic disease NS Symptoms NS Age NS Disease-free interval NS Origin of primary tumor Curative resection Abbreviation: NS, not significant.
4 100 Hemming et al Figure 4. There was no difference in outcome for patients with disease-free intervals (DFIs) greater or less than 36 months between the time of the original surgery and the time of the liver resection. therefore implied that selected patients with NCNNE metastases will potentially benefit from resection. The challenge is to accurately identify such patients and offer curative resection. Patients with noncolorectal GI-origin tumors metastatic to the liver clearly do poorly, with no 3-year survivors in either the present series or in the other largest single-center experience reported by Harrison et al. 6 Analyzing the present series along with 10 other series reported in the literature shows a 5-year survival rate of only 6% in patients with resected noncolorectal GI-origin hepatic metastases (2 of 33 patients) There are reported long-term survivors after liver resection for metastatic gastric cancer; however, these are primarily anecdotal reports. 16 In patients with direct hepatic extension of gastric cancer, en bloc hepatic resection may achieve extended survival. 13,16-19 However, there is little support for resecting discontinuous gastric metastases. There are also anecdotal reports of hepatic resection for pancreatic adenocarcinoma 20 ; however, the mean overall reported survival is only 18 months. 21 It would seem clear that hepatic resection of noncolorectal GI-origin metastases offers minimal benefit. Not surprisingly, patients with resections performed with positive margins did not do well, showing a median survival of 12 months. Although all patients in this series underwent surgery with curative intent, the poor outcome of patients undergoing resection with eventual positive margins provides indirect evidence against undertaking resection for palliation. The few reports of palliative resection of NCNNE tumors reported in the literature confirm the futility of this approach, with no long-term survivors. 6,7 One would intuitively expect patients with longer disease-free intervals to have less aggressive tumor biological characteristics and subsequently have improved outcome after hepatic resection. Alternatively, late hepatic metastases may represent escape from either immune surveillance or other tumor regulatory factors that subsequently signal a change to a more aggressive tumor behavior, in which case one would not see a difference in survival based on disease-free interval. In this series, neither the presence of synchronous versus metachronous metastases nor the diseasefree interval in patients with metachronous lesions could be shown to affect outcome. In contrast, several other series 6,7 have shown improved outcomes in patients with longer disease-free intervals before hepatic resection. However, these series also could not show differences in outcome in patients with synchronous versus metachronous liver metastases. The relatively small sample size and patient heterogeneity in all studies may explain the discrepancy between the present and other series. Resection of colorectal cancer metastases to liver is accepted as standard treatment in selected patients. Results of hepatic resection for colorectal cancer metastases from our institution 22 show a 34% overall 5-year survival rate, similar to the 5-year survival rate of 45% obtained for resection of NCNNE metastases. The natural history of unresected colorectal cancer metastatic to the liver has been well documented, with few patients surviving 5 years, 23 whereas to date, the natural history of hepatic metastases from NCNNE tumors has been less well defined. Evaluation of the natural history of hepatic metastases from NCNNE tumors, the effect of chemotherapy on natural history, and a comparison to resection is required to confirm the role of hepatic resection for NCNNE metastases. However, our study indicates that selected patients with NCNNE hepatic metastases who undergo curative resection will achieve prolonged survival. Therefore, liver resection should be considered for patients with disease resectable with curative intent who have primary tumors that do not arise from the GI tract. References 1. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15: Scheele J, Stang R, Attendorf-Hofmann A, Martin P. Resection of colorectal liver metastases. World J Surg 1995;19: Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, et al. Experience in hepatic resection for metastatic colorectal cancer. Analysis of clinical and pathological risk factors. Surgery 1994;116:
5 Noncolorectal Nonneuroendocrine Metastases McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108: Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg 1998;187: Harrison LE, Brennan MF, Newman E, Fortner JG, Picardo A, Blumgart LH, et al. Hepatic resection for noncolorectal nonneuroendocrine metastases: A fifteen-year experience with ninety six patients. Surgery 1997;121: Berney T, Mentha AD, Roth AD, Morel P. Results of surgical resection of liver metastases from non-colorectal primaries. Br J Surg 1998;85: Joyeux H, Saint-Aubert B, Szawlowski AW, Astre C, Solassol C. Chirurgie carcinologique pour des metastases hepatiques diffuses. A propos 30 cas. Chirurgie 1987;113: Stehlin JS Jr, de Ipolyi PD, Greeff PJ, McGaff CJ Jr, Davis BR, MvNary L. Treatment of cancer of the liver. Twenty year s experience with infusion and resection in 414 patients. Ann Surg 1988;208: Wolf RF, Goodnight JE, Krag DE, Schneider PD. Results of resection and proposed guidelines for patient selection in instances of noncolorectal hepatic metastases. Surg Gynecol Obstet 1991;173: Paineau J, Hamy A, Savigny B, Visset J. La resection des metastases hepatiques des cancers non colorectaux. Notre experience a propos de 20 observations. J Chir (Paris) 1995;132: Elias D, Lasser P, Spielmann M, May-Levin F, el Malt O, Thomas H, et al. Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast. Surg Gynecol Obstet 1991;172: Bines SD, England G, Deziel DJ, Witt TR, Doolas A, Roseman DL. Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors. Surgery 1993;114: Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft tissue sarcoma. Ann Surg 1995;221: Shirai Y, Tsukada K, Ohtani T, Watanabe H, Hatakeyama K. Hepatic metastases from carcinoma of the gallbladder. Cancer 1995;75: Ochiai T, Sasako M, Mizuno S, Kinoshita T, Takayama T, Kosuge T, et al. Hepatic resection for metastatic tumors from gastric cancer: An analysis of prognostic factors. Br J Surg 1994;81: Adam YG, Efron G. Trends and controversies in the management of carcinoma of the stomach. Surg Gynecol Obstet 1989;169: Korenaga D, Okamura T, Baba H, Saito A, Sugimachi K. Results of resection of gastric cancer extending to adjacent organs. Br J Surg 1988;75: Habu H, Saito N, Sato Y, Takeshita K, Sunagawa M, Endo M. Results of surgery in patients with gastric cancer extending to adjacent organs. Hepatogastroenterology 1990;37: Takamori H, Hiraoka T, Kanemitsu K, Tsuji T, Saito N, Nishida H, et al. Treatment strategies for hepatic metastases from pancreatic cancer in patients previously treated with radical resection combined with intraoperative radiation therapy. HPB Surg 1994;8: Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In: DeVita V, Hellman S, Rosenberg SA (eds). Cancer: Principles of oncology. Philadelphia: Lippincott, 1993; Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg 1997;173: Scheele J, Stangl R, Altendorf-Hohmann A. Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg 1990;77:
Although the liver is a frequent site for tumor metastases,
ORIGINAL ARTICLES Hepatic Resection for Noncolorectal Nonendocrine Liver Metastases Analysis of 1452 Patients and Development of a Prognostic Model René Adam, MD, PhD, Laurence Chiche, MD, Thomas Aloia,
More informationOutcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience
HPB, 2006; 8: 100/105 REVIEW ARTICLE Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience THOMAS A. ALOIA, RENÉ ADAM, DANIEL AZOULAY, HENRI BISMUTH & DENIS
More informationLiver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina
HPB, 2007; 9: 435439 ORIGINAL ARTICLE Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina J. LENDOIRE 1, M. MORO 2, O. ANDRIANI 3, J. GRONDONA
More informationSurgical treatment of neuroendocrine metastases
Best Practice & Research Clinical Gastroenterology Vol. 19, No. 4, pp. 577 583, 2005 doi:10.1016/j.bpg.2005.04.003 available online at http://www.sciencedirect.com 6 Surgical treatment of neuroendocrine
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationORIGINAL ARTICLE. A Second Liver Resection Due to Recurrent Colorectal Liver Metastases. accepted as the only curative
ORIGINAL ARTICLE A Second Liver Resection Due to Recurrent Colorectal Liver Metastases Antonio Sa Cunha, MD; Christophe Laurent, MD; Alexandre Rault, MD; Philippe Couderc, MD; Eric Rullier, MD; Jean Saric,
More informationRESEARCH ARTICLE. Qian Liu, Jian-Jun Bi, Yan-Tao Tian, Qiang Feng, Zhao-Xu Zheng, Zheng Wang* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Outcome after Simultaneous Resection of Gastric Primary Tumour and Synchronous Liver Metastases: Survival Analysis of a Single-center Experience in China Qian Liu, Jian-Jun Bi, Yan-Tao
More informationHepatobiliary and Pancreatic Malignancies
Hepatobiliary and Pancreatic Malignancies Gareth Eeson MD MSc FRCSC Surgical Oncologist and General Surgeon Kelowna General Hospital Interior Health Consultant, Surgical Oncology BC Cancer Agency Centre
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationORIGINAL ARTICLE. Surgical Resection for Metastatic Melanoma to the Liver. The John Wayne Cancer Institute and Sydney Melanoma Unit Experience
ORIGINAL ARTICLE Surgical Resection for Metastatic Melanoma to the Liver The John Wayne Cancer Institute and Sydney Melanoma Unit Experience D. Michael Rose, MD; Richard Essner, MD; T. Michael D. Hughes,
More informationClinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients
Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationLong-term Survival after Surgical Resection for Liver Metastasis from G astric Cancer: Two Case Reports
Cancer Res Treat. 2006;38(3):184-188 Long-term Survival after Surgical Resection for Liver Metastasis from G astric Cancer: Two Case Reports Jong Keun Lim, M.D. 1,4,5, Joong Bae Ahn, M.D., Ph.D. 1,4,5,
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationRisk factors for cancer recurrence or death within 6 months after liver resection in patients with colorectal cancer liver metastasis
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2016.90.5.257 Annals of Surgical Treatment and Research Risk factors for cancer recurrence or death within 6 months after
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationSECONDARIES: A PRELIMINARY REPORT
HPB Surgery, 1990, Vol. 2, pp. 69-72 Reprints available directly from the publisher Photocopying permitted by license only 1990 Harwood Academic Publishers GmbH Printed in the United Kingdom CASE REPORTS
More informationThe treatment and outcome of patients with soft tissue sarcomas and synchronous metastases
Sarcoma (2002) 6, 69 73 ORIGINAL ARTICLE The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases JOHN M. KANE III, J. WILLIAM FINLEY, DEBORAH DRISCOLL, WILLIAM G. KRAYBILL
More informationOutcomes of pancreaticoduodenectomy in patients with metastatic cancer
Korean J Hepatobiliary Pancreat Surg 2014;18:147-151 http://dx.doi.org/.14701/kjhbps.2014.18.4.147 Original Article Outcomes of pancreaticoduodenectomy in patients with metastatic cancer Joo Hwa Kwak,
More informationAppraisal of surgical resection of gallbladder cancer with special reference to lymph node dissection
Langenbeck s Arch Surg (2000) 385:509 514 DOI 10.1007/s004230000163 CURRENT CONCEPTS IN CLINICAL SURGERY Hiroshi Shimada Itaru Endo Yoshiro Fujii Noriyuki Kamiya Hideki Masunari Osamu Kunihiro Kuniya Tanaka
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationHepatic Resection is Safe for Metachronous Hepatic Metastases from Ovarian Cancer
182 Cancer Biol Niu Med et al. 2012; Hepatic 9: 182-187 Resection doi: for 10.7497/j.issn.2095-3941.2012.03.005 Ovarian Cancer Liver Metastases Original Article Hepatic Resection is Safe for Metachronous
More informationManagement of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationSurgical Metabolism Section, Surgery Branch, NCI, Bethesda, MD Division of Surgical Oncology, University of Maryland, Baltimore, MD
High Dose Intra-Arterial Melphalan Delivered via Percutaneous Hepatic Perfusion (PHP) for Patients with Unresectable Hepatic Metastases from Primary Neuroendocrine Tumors. James F. Pingpank, Richard E.
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationPulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience
Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience Clinton D. Kemp, MD,* R. Taylor Ripley, MD,* Aarti Mathur, MD, Seth M. Steinberg, PhD, Dao M. Nguyen,
More informationPAPER. Interval Hepatic Resection of Colorectal Metastases Improves Patient Selection
PAPE Interval Hepatic esection of Colorectal Metastases Improves Patient Selection aura A. ambert, MD; Thomas A. Colacchio, MD; ichard J. Barth, Jr, MD Hypothesis: Interval reevaluation for resectability
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationHepatic resection for colorectal liver metastases: prospective study
Key words: Colorectal neoplasms; Hepatectomy; Survival analysis CL Liu ST Fan CM Lo WL Law IOL Ng J Wong Hong Kong Med J 2002;8:329-33 The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road,
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationRadiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience
Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,
More informationSurgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital
Surgical Management of Pulmonary Metastases Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Introduction Lungs 2 nd most common site of metastatic deposition
More informationManagement of colorectal cancer liver metastases
Management of colorectal cancer liver metastases Aliakbarian M. M.D. Assistant professor of surgery Organ Transplant & Hepatopancreatobiliary Surgeon SUBJECTS The importance of surgical resection in colorectal
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationTREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
More informationIs Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?
Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Lee H, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Choi DW Department of Surgery, Samsung Medical Center Sungkyunkwan
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationDr Adam Bartlett. General Surgeon Senior Lecturer University of Auckland Auckland City Hospital
Dr Adam Bartlett General Surgeon Senior Lecturer University of Auckland Auckland City Hospital 11:05-11:15 Hepatic Metastectomy is Associated with Improved Survival Where is everyone? Hepatic Metastectomy
More informationCorrespondence should be addressed to Roland Andersson,
Gastroenterology Research and Practice Volume 2012, Article ID 568214, 4 pages doi:10.1155/2012/568214 Research Article Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More informationSurvival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.13.5195 Survival after Liver Metastasectomy in Colorectal Cancer Cases in Turkey RESEARCH ARTICLE Survival Outcomes of Liver Metastasectomy in Colorectal Cancer
More informationClinical Study Prognostic Factors Affecting Long-Term Survival after Resection for Noncolorectal, Nonneuroendocrine, and Nonsarcoma Liver Metastases
Hindawi Gastroenterology Research and Practice Volume 217, Article ID 5184146, 8 pages https://doi.org/1.1155/217/5184146 Clinical Study Prognostic Factors Affecting Long-Term Survival after Resection
More informationNEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS
University of Miami Jackson Memorial Hospital Role of the Surgeon in the Approach to Neuroendocrine tumors Dido Franceschi, MD Professor of Surgery University of Miami Karzinoide Siegfried Oberndorfer,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, pancreatic ductal, laparoscopic distal pancreatectomy for, 61 Adrenal cortical carcinoma, laparoscopic adrenalectomy for, 114
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationRetroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients
Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients INGO ALLDINGER 1,2, QIN YANG 3, CHRISTIAN PILARSKY 1, HANS-DETLEV SAEGER 1, WOLFRAM T. KNOEFEL
More informationEvaluation of prognostic scoring systems for bone metastases using single center data
MOLECULAR AND CLINICAL ONCOLOGY 3: 1361-1370, 2015 Evaluation of prognostic scoring systems for bone metastases using single center data HIROFUMI SHIMADA 1, TAKAO SETOGUCHI 2, SHUNSUKE NAKAMURA 1, MASAHIRO
More informationExtended multi-organ resection for ct4 gastric carcinoma: A retrospective analysis
Original Article Extended multi-organ resection for ct4 gastric carcinoma: A retrospective analysis 1. Longbin Xiao, 2. Mingzhe Li, 3. Fengfeng Xu, Department of General Surgery I, 4. Huishao Ye, Department
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationHIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
More informationt I Hepatic Resection for Metastatic Colorectal Adenocarcinoma: A Proposal of a Prognostic Scoring System I ~:
Hepatic Resection for Metastatic Colorectal Adenocarcinoma: A Proposal of a Prognostic Scoring System Shunzaburo Iwatsuki MD PhD FACS Igor Dvorchik phd Juan R Madariaga MD FACS J Wallis Marsh MD FACS Forrest
More informationSimultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastasis
Simultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastasis Robert Martin, MD, Philip Paty, MD, Yuman Fong, MD, FACS, Andrew Grace, MD, Alfred Cohen, MD, FACS, Ronald
More informationRepeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome.
Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome. Jönsson, Kristoffer; Gröndahl, Gerd; Salö, Martin; Tingstedt,
More informationClinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter
Hindawi Publishing Corporation Journal of Oncology Volume 2008, Article ID 212067, 5 pages doi:10.1155/2008/212067 Clinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter
More informationManagement of Rare Liver Tumours
Gian Luca Grazi Hepato-Biliary-Pancreatic Surgery National Cancer Institute Regina Elena Rome Fibrolamellar Carcinoma Mixed Hepato Cholangiocellular Carcinoma Hepatoblastoma Carcinosarcoma Primary Hepatic
More informationRelevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer
Relevance of an Intensive Postoperative Follow-up After Surgery for Non Small Cell Lung Cancer Virginie Westeel, MD, Didier Choma, MD, François Clément, MD, Marie-Christine Woronoff-Lemsi, PhD, Jean-François
More informationSurgical Therapy of GEP-NET: An Overview
Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior
More informationColorectal Liver Metastases Metachronous
Colorectal Liver Metastases Metachronous Professor Rowan Parks Professor of Surgical Sciences University of Edinburgh No disclosures Natural History of Unresected Untreated Colorectal Metastases Year N
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationThe Surgical Management of Colorectal Metastases
11th July 2017 Bowel Cancer UK The Surgical Management of Colorectal Metastases Ben Cresswell MD(Res) FRCS Consultant HPB Surgeon The Basingstoke Hepatobiliary Unit United Kingdom Surgical Management of
More informationAggressive surgery in the multimodality treatment of liver metastases from colorectal cancer
Journal of BUON 12: 209-213, 2007 2007 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer N.
More informationThe role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery
DOI:10.1111/hpb.12306 HPB ORIGINAL ARTICLE The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery Prejesh Philips, Erik Dunki-Jacobs,
More informationPulmonary metastasectomy in uterine malignancies: outcome and prognostic factors
Original Article Pulmonary metastasectomy in uterine malignancies: outcome and prognostic factors Marco Anile, Sara Mantovani, Ylenia Pecoraro, Carolina Carillo, Lorenzo Gherzi, Andreina Pagini, Erino
More informationOncologic outcomes following metastasectomy in colorectal cancer patients developing distant metastases after initial treatment
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2015.88.5.253 Annals of Surgical Treatment and Research Oncologic outcomes following metastasectomy in colorectal cancer
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationThe Frequency and Significance of Small (15 mm) Hepatic Lesions Detected by CT
535 Elizabeth C. Jones1 Judith L. Chezmar Rendon C. Nelson Michael E. Bernardino Received July 22, 1991 ; accepted after revision October 16, 1991. Presented atthe annual meeting ofthe American Aoentgen
More informationGastrinoma: Medical Management. Haley Gallup
Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical
More informationHEPATIC METASTASES. We can state 3 types of metastases depending on their treatment options:
HEPATIC METASTASES 1. Definition Metastasis means the spread of cancer. Cancerous cells can separate from the primary tumor and enter the bloodstream or the lymphatic system (the one that produces, stores,
More informationLow-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
Med Oncol (2014) 31:870 DOI 10.1007/s12032-014-0870-2 ORIGINAL PAPER Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer Jasmine Miger Annika Holmqvist Xiao-Feng Sun Maria Albertsson
More informationNatural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry
2015;112:872 876 Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry PETER L. JERNIGAN, MD, KOFFI WIMA, MS, DENNIS J. HANSEMAN, PhD, RICHARD
More informationA Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer
The Oncologist Gynecologic Oncology A Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer DENNIS S. CHI, a REBECCA PHAËTON,
More informationHow to deal with synchronous primary and liver metastases
How to deal with synchronous primary and liver metastases Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB) Department of Surgery.
More informationDEPARTMENT OF ONCOLOGY ELECTIVE
DEPARTMENT OF ONCOLOGY ELECTIVE 2015-2016 www.uwo.ca/oncology Oncology Elective Program Administrator: Ms. Kimberly Trudgeon Room A4-901C (Admin) LHSC London Regional Cancer Centre (Victoria Campus) Phone:
More informationSurgical treatment in non-small cell lung cancer with pulmonary oligometastasis
He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationManagement of Liver Metastasis from Colorectal Carcinoma. Aisha White, M.D. SUNY Downstate Division of Transplantation
Management of Liver Metastasis from Colorectal Carcinoma Aisha White, M.D. SUNY Downstate Division of Transplantation Management of Colorectal Liver Metastasis Epidemiology 25% of patients diagnosed
More informationTreatment Strategy for Non-curative Resection of Early Gastric Cancer. Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea
Treatment Strategy for Non-curative Resection of Early Gastric Cancer Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea Classic EMR/ESD data analysis style Endoscopic resection
More informationHepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis
Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis Ryan T Groeschl, MD, Ido Nachmany, MD, Jennifer L Steel, PhD, Srinevas K Reddy, MD, Evan S Glazer, MD,
More informationThe impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis
Received: 1 May 2017 Accepted: 23 May 2017 DOI: 10.1002/jso.24727 RESEARCH ARTICLE The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationPulmonary Resection for Metastases from Colorectal Cancer
ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationMultidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers
Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network
More informationMultidisciplinary management of retroperitoneal sarcomas
Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationPrognostic Factors and Survival after Pulmonary Resection ofmetastaticrenalcellcarcinoma
European Urology European Urology 48 (2005) 77 82 Kidney Cancer Prognostic Factors and Survival after Pulmonary Resection ofmetastaticrenalcellcarcinoma Hans-Stefan Hofmann*, Heinz Neef, Katharina Krohe,
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationHepatic Resection of Metastatic Testicular Carcinoma: A Further Update
Annals of Surgical Oncology, 6(7):640 644 Published by Lippincott Williams & Wilkins 1999 The Society of Surgical Oncology, Inc. Hepatic Resection of Metastatic Testicular Carcinoma: A Further Update Tara
More informationColor Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging
Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:
More information